Pharmacist's Letter | CE & Recommendations You Can Trust

December 2023 Issue

Help Answer Questions About 2024 Medicare Part D Changes

Patients will ask about changes coming to Medicare Part D in 2024...

Resources

Technician Tutorial: Billing Rx Drugs

Compare Nalmefene and Naloxone for Opioid Overdose Reversal

New Rx nalmefene nasal spray (Opvee) will join naloxone as an option to reverse opioid overdose...

Navigate Risk of Ketoacidosis Due to an SGLT2 Inhibitor

You’ll need to know how to manage risk of ketoacidosis due to SGLT2 inhibitors (dapagliflozin, etc)...

Expect a Limited Role for Colchicine in Reducing CV Risk

You’ll get questions about the role of new Rx colchicine (Lodoco) for patients with chronic coronary disease...

GO TO FULL ISSUE

CE & Training

INTERACTIVE SELF-STUDY CE: Acute Coronary Syndrome: Risk Factors and Diagnosis

CE IN THE LETTER: Pharmacist's Letter December 2023

LIVE CE: Pharmacy Essential Updates December 2023

PODCAST CE: Managing Chronic Coronary Disease

GO TO CE & TRAINING ORGANIZER >

Free Clinical Resources

Meds That Should Not Be Crushed

COVID-19 Vaccines

GO TO ALL CLINICAL RESOURCES >

What is Pharmacist’s Letter?

Pharmacist's Letter is the resource trusted by over 200,000 pharmacists for staying current on medication recommendations and taking and tracking CE. Learn more >

Developing Your Pharmacy Career

Pharmacist's Letter is one of many CE and training solutions from TRC Healthcare. We support pharmacists like you at all stages of their career. Learn more about:

Solutions for Hospital Pharmacists

Advanced Resources for Natural Medicines

Training on Cannabis for Pharmacists